The authors said it is the first study of epidemiology and real-world treatment in Germany.
A recent study examining the incidence and prevalence of myasthenia gravis (MG) in Germany shows the rare disease is high compared with other European countries, with many patients untreated and carrying a high burden of illness.
The authors said it is the first study of epidemiology and real-world treatment in Germany, based on 3.4 million insured individuals from January 1, 2015, to December 31, 2019.
The retrospective cohort study was based on anonymized claims data from the German statutory health insurance fund AOK PLUS, and included the federal states of Saxony and Thuringia, corresponding to around 4% of the total population and 4.7% of all people with statutory health insurance.
Two patient cohorts were defined: newly diagnosed, or incident patients, between 2015 to 2019, as well as those with existing, or prevalent MG, in 2019.
Incident patients, with a mean age of 66.9 years, totaled 775; prevalent patients, with a mean age of 68.6 years, totaled 1247.
Prevalence was estimated to be 39.3/100,000 at the end of 2019. The incidence in 2019 was 4.6 cases/100,000 persons, which the authors said was higher than cited in previous research, which relied mainly on hospital records and therefore might be underestimated.
The 12-month mortality rate was 5.7%, higher than the 1.1% seen in the general population.
The authors wrote that they were surprised to find that a little more than a third (31.5%) of newly diagnosed patients had no treatment for MG in the first year. While 5.0% of those patients had a total follow-up time of less than 90 days and may not have been able to start therapy within that time, it is unknown why the other 25% of the incident cohort were not treated, the authors said.
In addition, 29.9% experienced an exacerbation, and 6.7% a myasthenic crisis.
Within the incident cohort, pyridostigmine (60.4%), oral corticosteroids (39.4%), and azathioprine (26.8%) were the most frequently prescribed drugs; 4.4% had a thymectomy; and 9.3% were given IViG.
Azathioprine has a slow onset of action, often taking 1 to 2 years to take full effect, the authors noted.
Notably, within the first year of diagnosis, 31.0% of patients experienced exacerbations and myasthenic crises (29.9% with exacerbations, 6.7% with myasthenic crises).
“Despite current treatment options, the burden of disease remains very high for many MG patients, with refractory courses, psychiatric comorbidities, and myasthenic exacerbations and crises,” the authors said.
In addition, they wrote, “existing treatments do not target the specific antibodies and usually do not induce a full remission without the need for further therapy.”
Reference
Mevius A, Lars Jöres L, Biskup J. Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany. Neuromuscul Disord. Published online March 1, 2023. doi:10.1016/j.nmd.2023.02.002
Investigators Explore Potential Link Between the Gut Microbiome and Myasthenia Gravis Risk
November 14th 2023This new study sought to solidify a relationship between certain microbes in intestinal flora and the risk of developing myasthenia gravis, specifically those potentially reducing that risk.
Read More
Racial Disparities in Acute Care Utilization Seen Among Patients With Myasthenia Gravis
November 11th 2023Research presented at the 2023 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting emphasizes the potential need for patient support programs targeting at-risk populations to enhance disease management and reduce acute care utilization in myasthenia gravis.
Read More
Myasthenia Gravis Potential Result of Cancer Treatment
November 8th 2023When patients are undergoing treatment for cancer, clinicians should be aware of the potential to develop myasthenia gravis from immune checkpoint inhibitors (ICI), new research stresses, with ongoing surveillance and risk factor identification becoming necessary steps.
Read More
SDOH Lead to Greater Suboptimal Treatment Response in Myasthenia Gravis
November 3rd 2023A retrospective study presented at the 2023 American Association of Neuromuscular and Electrodiagnotsic Medicine meeting revealed that social determinants of health (SDOH) are linked to poorer treatment outcomes in patients who have myasthenia gravis, emphasizing the need for identifying and supporting at-risk individuals.
Read More